Targeted therapy for breast cancer, including tamoxifen and trastuzumab, are utilized for ER/PR-positive and HER2-positive breast cancers, respectively [5,6]; however, they are ineffective against triple-negative breast cancer (TNBC) due to the lack of these receptors. This evidence concerns the gene ERBB2 and breast cancer.